{"analyses":[{"ciLowerLimit":"35.18","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"58.99","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Difference in Percentage","paramValue":"47.1","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2"},{"groupId":"OG001","value":"73.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"ASAS 20 defined as 20 percent (%) improvement compared to baseline in the ASAS Working Group criteria: that is, greater than or equal to (\\>=)20% improvement from baseline in at least 3 of the 4 domains: patient's global assessment of disease activity (0=very well,10 =very poor), total back pain (0=no pain,10=most severe pain), function (self-assessment using BASFI \\[0=no functional impairment to 10= maximal impairment\\]), inflammation (0=none,10=very severe) with an absolute improvement of at least 1 (0-10 centimeter (cm) visual analogue scale \\[VAS\\]), and an absence of deterioration (defined as \\>=20% worsening and absolute worsening of at least 1 on a 0-10 cm scale) in the potential remaining domain.","groups":[{"description":"Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.","id":"OG000","title":"Group 1: Placebo Then Golimumab"},{"description":"Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.","id":"OG001","title":"Group 2: Golimumab"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) included all participants who were randomized in the study.","reportingStatus":"POSTED","timeFrame":"Week 16","title":"Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}